Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) announced it is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility. The company is conducting a comprehensive technical, regulatory, economic, and logistical analysis of candidate sites, with key criteria including proximity to iodine brine sources, logistics, infrastructure, access to skilled labor, and government incentive packages.
Strong candidate locations have been identified in Oklahoma and Texas due to their compelling attributes, such as proximity to Voyageur's iodine extraction initiatives in Oklahoma's Anadarko Basin, robust transportation infrastructure, and competitive business climates. The company is actively engaging with economic development authorities across multiple U.S. jurisdictions to secure the most attractive incentive and support packages.
The facility will receive concentrated iodine liquor from Voyageur's proprietary closed-loop Streamlined Iodine Process directly from its Oklahoma brine operations, alongside high-purity barite from the Frances Creek project. Unlike conventional manufacturers that rely on imported iodine flakes or intermediates and energy-intensive synthetic precipitated barium sulfate, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading into USP-grade material and sterile injectable manufacturing. Management believes this will deliver the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost, with superior sustainability and supply security.
Key anticipated project highlights include cost leadership through vertical integration, significant opportunities for U.S. federal and state funding and incentives, creation of 150–250 direct high-skilled jobs, and substantial economic activity and tax revenue. The facility is expected to support workforce development through planned collaboration with post-secondary institutions and enhance supply chain security by enabling efficient management of iodine and barium contrast production.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: “This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. The jurisdiction that provides Voyageur with the most significant incentive package will secure this transformative project and its substantial long-term economic benefits.”
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing, regulatory approvals, and other conditions. This announcement builds on Voyageur's ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use.
